Evidence mapPaperPMID 28721135Full record

ArticleArchives of medical science : AMS2017

A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study.

Tomáš Štulc, Věra Lánská, Michaela Šnejdrlová, Michal Vrablík, Martina Prusíková, Richard Češka

Open access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tomáš Štulc3 Department of Internal Medicine, 1 Faculty of Medicine, Charles University, Prague, Czech Republic.
Věra LánskáDivision of Professional Activities, Quality Assurance and Controlling, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Michaela Šnejdrlová3 Department of Internal Medicine, 1 Faculty of Medicine, Charles University, Prague, Czech Republic.
Michal Vrablík3 Department of Internal Medicine, 1 Faculty of Medicine, Charles University, Prague, Czech Republic.
Martina Prusíková3 Department of Internal Medicine, 1 Faculty of Medicine, Charles University, Prague, Czech Republic.
Richard Češka3 Department of Internal Medicine, 1 Faculty of Medicine, Charles University, Prague, Czech Republic.
Charles University · CZInstitute of Clinical and Experimental Medicine · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of study was to investigate the possibility of cardiovascular risk improvement through systematic identification of high-risk individuals and treatment in accordance with current guidelines using modern therapy in daily clinical practice. MATERIAL AND

methodsTwo hundred and sixty-three physicians participated in the study. The physicians were asked to screen for cardiovascular risk factors in patients presenting with unrelated problems and to re-evaluate the attainment of treatment goals in those with already known risk factors. Each physician enrolled up to 20 consecutive patients with hypertension and/or hyperlipidemia. A total of 3015 patients were included. Cardiovascular risk was assessed using the SCORE system. Risk factors were treated in accordance with current national guidelines. The therapy of hyperlipidemia and hypertension was preferentially based on rosuvastatin, amlodipine and valsartan. Further medication was at the discretion of the attending physician. Patients were examined at baseline and after 3 and 6 months.

resultsThe principal result is that global cardiovascular risk decreased by 35% (from 8.9 ±6.4 to 5.9 ±4.4,

conclusionsThe VARO study demonstrates that in daily practice settings, both individual risk factors and global cardiovascular risk are significantly improved through the systematic identification of high-risk individuals and their treatment in accordance with current guidelines using modern pharmacotherapy.

Indexed as

cardiovascular risk reductiondyslipidemiaglobal cardiovascular riskguidelines implementationhypertension

Identifiers

PMID28721135
PMCPMC5510513
OpenAlexW2587977230

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.